Comparison of the efficacy of triple versus quadruple therapy on the Chinese patients with chronic gastritis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16009411

Enrollment

Unknown

Registered

2016-10-14

Start date

2011-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori related chronic gastritis

Interventions

1:the standard triple therapy for H. pylori

2:Bismuth-containing quadruple therapy for H. pylori

Eligibility

Sex/Gender

All

Age

19 Years to 81 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 years and elder; 2. with confirmed H. pylori related chronic gastritis.

Exclusion criteria

Exclusion criteria: Those who had received H. pylori eradication therapy or anti-secretory therapy; use of antibiotics, bismuth salts, proton pump inhibitors or non-steroidal anti-inflammatory drugs within 2 months; history of gastrectomy

Design outcomes

Primary

Measure	Time frame
H. pylori eradication rates;	—

Secondary

Measure	Time frame
clinical symptoms;Histologic assessment;	—

Countries

China

Contacts

Public ContactLiangjing Wang

Second Affiliated Hospital, School of Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China

wanglj76@hotmail.com+86 13777848083

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026